- Pharyngitis and/or tonsillitis
- Acute bacterial otitis media
- Acute bacterial maxillary sinusitis
- Lower respiratory tract infections including pneumonia
- Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis
- Skin and Skin-Structure Infections
- Urinary tract infections
- Bone and Joint infections
- Gonorrhea: Uncomplicated and disseminated gonococcal infections
- Early Lyme disease (erythema migrans)
- Switch therapy (injectable to oral) after surgery when patient’s condition is improved.
Clavulanic acid has a similar structure to the beta-lactam antibiotics but binds irreversibly to the beta-lactamase enzymes.
Clavulanic acid protects Cefuroxime from degradation by beta-lactamase enzymes and effectively extends the antibacterial spectrum of Cefuroxime to include many bacteria normally resistant to Cefuroxime and other cephalosporins.
Acute bacterial maxillary sinusitis: 250 mg twice daily for 10 days
Acute bacterial exacerbation of chronic bronchitis: 250-500 mg twice daily for 10 days
Secondary bacterial infections of acute bronchitis: 250-500 mg twice daily for 5-10 days
Community acquired pneumonia: 250-500 mg twice daily for 5-10 days
Uncomplicated skin & skin-structure infections: 250-500 mg twice daily for 10 days
Multidrug resistant typhoid fever: 500 mg twice daily for 10-14 days
Uncomplicated urinary tract infection: 250 mg twice daily for 7-10 days
Uncomplicated gonorrhea: 1000 mg once single dose
Lyme disease: 500 mg twice daily for 20 days
Antacids: Drugs that reduce gastric acidity may result in a lower bioavailability of Cefuroxime and Clavulanic acids compared with that of fasting state and tend to cancel the effect of postprandial absorption.
Oral contraceptives: In common with other antibiotics, Cefuroxime may affect the gut flora, leading to lower estrogen re absorption and reduced efficacy of combined oral estrogen/ progesterone.